A Phase 1, Multiple-Dose, Dose-Escalation Trial of PT2385 Tablets, a HIF-2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma

Trial Profile

A Phase 1, Multiple-Dose, Dose-Escalation Trial of PT2385 Tablets, a HIF-2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Jun 2017

At a glance

  • Drugs Nivolumab (Primary) ; PT 2385 (Primary)
  • Indications Renal cancer; Renal cell carcinoma
  • Focus Adverse reactions; First in man
  • Sponsors Peloton Therapeutics
  • Most Recent Events

    • 29 Sep 2016 Planned number of patients changed from 101 to 151.
    • 29 Sep 2016 Planned End Date changed from 1 Dec 2017 to 1 Sep 2018.
    • 29 Sep 2016 Planned primary completion date changed from 1 Jun 2017 to 1 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top